

Uppsala, 2019-02-01

PRESS RELEASE

QuiaPEG carries out directed new issue of shares and warrants

QuiaPEG Pharmaceuticals Holding AB (publ), "QuiaPEG", today announces that the company has decided on a directed new issue of shares and warrants to three investors.

QuiaPEG Pharmaceuticals Holding AB ("the Company"), listed on Spotlight, today announces that the Company's Board of Directors made the decision on February 1, 2019, with the support of authorization from the Annual General Meeting on June 18, 2018, to carry out a directed new issue of 2,058,824 shares and 2,058,824 warrants.

The new issue of shares comprises a subscription amount of SEK 7,000,001,6. The warrants are issued without consideration and have a term of nine months. The subscription price for the warrants amounts to SEK 3.40. In the event of full utilization of the warrants, the Company would receive an additional SEK 7,000,001,6. The issue of shares and warrants is directed to a group consisting of the existing owners Nyenburgh Holding B.V., Gerhard Dal and Johan Thorell.

The company intends to use the proceeds from the issue primarily for the commercialization of Uni-Qleaver® and the development of the Company's internal drug projects.

Main terms for the new share issue

- The company's share capital shall be increased by a maximum of SEK 1,852,941.6 through a new issue of a maximum of 2,058,824 shares.
- The right to subscribe for new shares shall, with deviation from the shareholders' preferential rights, apply to Nyenburgh Holding B.V., Gerhard Dal and Johan Thorell.
- The new shares will be subscribed for at a price of SEK 3.40 per share. The rate has been determined taking into account the share's volume-weighted average price and after thorough discussions with the subscribers at arm's length.

- Subscription of new shares shall take place on subscription lists which shall be made available to the subscribers. Subscription must take place no later than February 15, 2019. However, the Board of Directors shall have the right to extend the subscription period.
- Payment of SEK 3.40 per subscribed share shall be paid in cash by February 15, 2019 at the latest.
- The new shares entitle the holder to a dividend for the first time on the record date for dividends that occurs immediately after the new share issue has been registered with the Swedish Companies Registration Office and the shares have been entered in the share register of Euroclear Sweden AB.

Main terms for the new issue of warrants

- A maximum of 2,058,824 warrants entitled to subscribe for new shares in the Company shall be issued.
- The right to subscribe for the warrants shall, with deviation from the shareholders' preferential rights, accrue to Nyenburgh Holding B.V., Gerhard Dal and Johan Thorell.
- The warrants are issued without consideration.
- Subscription of the warrants shall take place on a subscription list which shall be made available to the subscribers. Subscription must take place no later than February 15, 2019. However, the Board of Directors shall have the right to extend the subscription period.
- Each warrant entitles the holder to subscribe for one share in the Company with a quota value of SEK 0.9, which means that the share capital can be increased by a maximum of SEK 1,852,941.6 upon full exercise of the warrants by subscription of a maximum of 2,058,824 new shares.
- The warrants may be exercised for subscription of shares in the Company during the period from the date of issue of the warrants until November 1, 2019.
- The subscription price per share shall be SEK 3.40 per share.
- Shares issued after subscription under these terms entail the right to dividend for the first time on the record date for dividends that occur immediately after the new issue has been

registered with the Swedish Companies Registration Office and the shares have been entered in the share register of Euroclear Sweden AB.

- Upon full exercise of the warrants, the dilution effect will correspond to approximately 5.7 per cent of the share capital and votes, taking into account the full exercise of all outstanding warrants in the Company. The dilution effect has been calculated by dividing the number of warrants by the sum of all the Company's outstanding shares (before the above-mentioned new issue of shares) and the number of shares that outstanding warrants may give rise to.

Reason for deviation from shareholders' preferential rights

The reason for deviation from the shareholders' preferential rights is that the Board of Directors judge that a targeted issue is more suitable for the company for reasons of time and cost, i.e. that a targeted issue is more rapid, less costly and takes fewer resources internally. The company's human resources are limited and a rights issue risks hampering the company's daily operations in the current situation. All in all, the Board of Directors believes that the above-stated indicates with sufficient strength that it is in the company's and shareholders' interest to carry out an issue with deviation from the shareholders' preferential rights.

Reasons for the issue price

The issue of shares and warrants in itself constitutes a package offer to the subscribers and each is conditional on the other. The share issue price of SEK 3.40 corresponds to a discount of approximately 1.1 percent against the share's volume-compensated average price during the period January 17, 2018 - January 30, 2018.

The issue in its entirety (shares plus warrants) entails a discount of about 12 percent or 41 öre, calculated on the basis that the current value of the warrants is 37 öre per option. The present value has been calculated according to the Black & Scholes model, based on the volume-weighted average price for the company's share during the period January 17, 2019 - January 30, 2019, which was SEK 3.44. The issue discount has been assessed by the Board as market-based in this context.

For further information contact:

Marcus Bosson

CEO

QuiaPEG Pharmaceuticals Holding AB



Tel: +46 (0) 70 693 12 53
marcus.bosson@quiapeg.com

www.quiapeg.com

This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the above contact person, for publication on February 1, 2019.

About QuiaPEG

QuiaPEG Pharmaceuticals Holding AB (publ) is a development company for pharmaceuticals based on a patented so-called drug-delivery platform, Uni-Qleaver®. The company develops improved and patentable forms of drugs in development or that have already been approved by pharmaceutical authorities. These refined and improved forms of pharmaceuticals are based on the company's unique and patented technology platform.